MX2013001402A - Proceso para preparar tubulisinas. - Google Patents

Proceso para preparar tubulisinas.

Info

Publication number
MX2013001402A
MX2013001402A MX2013001402A MX2013001402A MX2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A
Authority
MX
Mexico
Prior art keywords
processes
tubulysins
naturally occurring
preparing
preparing tubulysins
Prior art date
Application number
MX2013001402A
Other languages
English (en)
Inventor
Iontcho Radoslavov Vlahov
Christopher Paul Leamon
Katheryn Marie Stanford
Michael Groaning
Paul Joseph Kleindl
Hari Krishna R Santhapuram
Fei You
Kevin Yu Wang
Le-Cun Xu
Allen Ritter
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of MX2013001402A publication Critical patent/MX2013001402A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Las tubulisinas son una serie de agentes citotóxicos de origen natural que son de interés como agentes terapéuticos anticancerosos. Se describen los procesos e intermediarios útiles para preparar las tubulisinas de origen natural y de origen no natural y los análogos y derivados de las mismas.
MX2013001402A 2010-08-06 2011-08-05 Proceso para preparar tubulisinas. MX2013001402A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37143310P 2010-08-06 2010-08-06
PCT/US2011/046797 WO2012019123A1 (en) 2010-08-06 2011-08-05 Processes for preparing tubulysins

Publications (1)

Publication Number Publication Date
MX2013001402A true MX2013001402A (es) 2013-08-29

Family

ID=45559842

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001402A MX2013001402A (es) 2010-08-06 2011-08-05 Proceso para preparar tubulisinas.

Country Status (12)

Country Link
US (3) US8889880B2 (es)
EP (1) EP2600866A4 (es)
JP (1) JP2013535220A (es)
KR (1) KR20130096712A (es)
CN (1) CN103140227B (es)
AU (1) AU2011285532B2 (es)
BR (1) BR112013003004A2 (es)
CA (1) CA2807511A1 (es)
EA (1) EA025471B1 (es)
MX (1) MX2013001402A (es)
SG (1) SG187728A1 (es)
WO (1) WO2012019123A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
AU2011285532B2 (en) 2010-08-06 2015-09-10 Endocyte, Inc. Processes for preparing tubulysins
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP2908818A4 (en) 2012-10-16 2016-07-13 Endocyte Inc CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
JP6863888B2 (ja) 2014-10-01 2021-04-21 メディミューン，エルエルシー ポリペプチドをコンジュゲートさせる方法
HK1248069A1 (zh) * 2015-02-25 2018-10-12 William Marsh Rice University 去乙酰氧基微管溶素h及其类似物
SMT202000285T1 (it) 2015-11-10 2020-07-08 Medimmune Llc Molecole di legame specifiche per asct2 e loro usi
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN108495653A (zh) 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
US10988546B2 (en) 2017-08-01 2021-04-27 Medimmune, Llc BCMA monoclonal antibody-drug conjugate
US11274124B2 (en) 2017-11-29 2022-03-15 William Marsh Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
CR20230146A (es) 2020-09-11 2023-06-07 Medimmune Ltd Moléculas de unión a b7-h4 terapéuticas
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
US12065496B2 (en) 2021-11-10 2024-08-20 Astrazeneca Ab Antibody molecules and conjugates
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
EP4543920A1 (en) 2022-06-27 2025-04-30 Astrazeneca AB Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
AU2003266233A1 (en) 2002-07-09 2004-01-23 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel tubulysin analogues
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
DE102009032972A1 (de) 2009-07-14 2011-01-20 Erbe Elektromedizin Gmbh Vorrichtung zur Herstellung von Anastomosen
WO2011069116A1 (en) 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
AU2011285532B2 (en) * 2010-08-06 2015-09-10 Endocyte, Inc. Processes for preparing tubulysins

Also Published As

Publication number Publication date
US20150225447A1 (en) 2015-08-13
CN103140227A (zh) 2013-06-05
EP2600866A1 (en) 2013-06-12
US8889880B2 (en) 2014-11-18
CA2807511A1 (en) 2012-02-09
US9273091B2 (en) 2016-03-01
EP2600866A4 (en) 2013-12-11
US20130137139A1 (en) 2013-05-30
KR20130096712A (ko) 2013-08-30
US20160177363A1 (en) 2016-06-23
JP2013535220A (ja) 2013-09-12
US9499849B2 (en) 2016-11-22
WO2012019123A1 (en) 2012-02-09
HK1185558A1 (zh) 2014-02-21
CN103140227B (zh) 2016-01-20
EA201390203A1 (ru) 2013-08-30
BR112013003004A2 (pt) 2016-06-14
AU2011285532A1 (en) 2013-02-21
SG187728A1 (en) 2013-03-28
EA025471B1 (ru) 2016-12-30
AU2011285532B2 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
MX2013001402A (es) Proceso para preparar tubulisinas.
MD20150091A2 (ro) Compuşi antivirali
SG190785A1 (en) Antiviral compounds
MX349004B (es) Nuevos compuestos.
MY168300A (en) Pharmaceutical Composition for Inhalation
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2015DN01119A (es)
MX2013004061A (es) Analogos de ciclosporina.
PH12014502032A1 (en) Treatment of brain cancer
MX2014004196A (es) Citramida de rasagilina.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
PL402710A1 (pl) Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania
MX348393B (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
MX2013004062A (es) Analogos de ciclosporina.
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
IN2014DN03010A (es)
PH12013500210A1 (en) Highly crystalline valsartan
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
IN2013MU03317A (es)
MX351961B (es) Analogos de diazonamida.
MX2013005624A (es) Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica.
TN2013000035A1 (en) Highly crystalline valsartan

Legal Events

Date Code Title Description
FG Grant or registration